REVIEW ARTICLE
The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation
Kai Ma,
Heqiao Han,
Yuchen Bao,
Rongtao Chen,
Yixuan Yang,
Wenwei Shao,
Kai Ma
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Search for more papers by this authorHeqiao Han
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Search for more papers by this authorYuchen Bao
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorRongtao Chen
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorYixuan Yang
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorCorresponding Author
Wenwei Shao
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Medical School of Tianjin University, Tianjin, China
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin University, Tianjin, China
Correspondence:
Wenwei Shao ([email protected])
Search for more papers by this authorKai Ma,
Heqiao Han,
Yuchen Bao,
Rongtao Chen,
Yixuan Yang,
Wenwei Shao,
Kai Ma
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Search for more papers by this authorHeqiao Han
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Search for more papers by this authorYuchen Bao
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorRongtao Chen
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorYixuan Yang
Medical School of Tianjin University, Tianjin, China
Search for more papers by this authorCorresponding Author
Wenwei Shao
Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
Medical School of Tianjin University, Tianjin, China
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin University, Tianjin, China
Correspondence:
Wenwei Shao ([email protected])
Search for more papers by this authorFirst published: 05 March 2025
Funding: This study was supported by the Youth Fund of the National Natural Science Foundation of China (82101853) and the National Key Research and Development Program of China (2022YFF1202903).
Kai Ma and Heqiao Han contributed equally to this study.
ABSTRACT
Immune checkpoints are important molecules that regulate the immune response, preventing its overactivation from causing tissue damage and autoimmune diseases. B and T lymphocyte attenuator (BTLA) plays an important role in regulating the activation and suppression of the immune response as part of a bidirectional signaling complex. The BTLA and its ligand herpesvirus entry mediator (HVEM) interaction transmits inhibitory signals that suppress the biological activity of T cells, B cells, and DCs. In addition, BTLA–HVEM can affect the induction of Treg cells, further suggesting its important role in immune regulation. Organ transplantation is the ultimate treatment option for many patients with end-stage organ failure. Transplant rejection can cause damage to the transplanted organ, which seriously affects the prognosis of patients. Therefore, we would like to explore the potential application value of the BTLA–HVEM interaction to exert an immunosuppressive function and thus attenuate transplant rejection. We first reviewed the structure and function of BTLA and HVEM, then summarized their research progress in organ transplantation, and further explored the directions of potential future applications and the challenges of current BTLA–HVEM applications.
Disclosure
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The authors have nothing to report.
References
- 1J. H. Esensten, Y. A. Helou, G. Chopra, A. Weiss, and J. A. Bluestone, “CD28 Costimulation: From Mechanism to Therapy,” Immunity 44, no. 5 (2016): 973–988.
- 2K. Ciesielska-Figlon and K. A. Lisowska, “The Role β of the CD28 Family Receptors in T-Cell Immunomodulation,” International Journal of Molecular Sciences 25, no. 2 (2024): 1274, https://doi.org/10.3390/ijms25021274.
- 3S. Van Coillie, B. Wiernicki, and J. Xu, “Molecular and Cellular Functions of CTLA-4,” Advances in Experimental Medicine and Biology 1248 (2020): 7–32.
- 4H. Arasanz, M. Gato-Canas, M. Zuazo, et al., “PD1 Signal Transduction Pathways in T Cells,” Oncotarget 8, no. 31 (2017): 51936–51945.
- 5C. Battin, J. Leitner, P. Waidhofer-Söllner, K. Grabmeier-Pfistershammer, D. Olive, and P. Steinberger, “BTLA Inhibition Has a Dominant Role in the Cis-Complex of BTLA and HVEM,” Frontiers in Immunology 13 (2022): 956694.
- 6M. Collin and V. Bigley, “Human Dendritic Cell Subsets: An Update,” Immunology 154, no. 1 (2018): 3–20.
- 7K. Wojciechowicz, M. Spodzieja, K. A. Lisowska, and A. Wardowska, “The Role of the BTLA–HVEM Complex in the Pathogenesis of Autoimmune Diseases,” Cellular Immunology 376 (2022): 104532.
- 8C. Paluch, A. M. Santos, C. Anzilotti, R. J. Cornall, and S. J. Davis, “Immune Checkpoints as Therapeutic Targets in Autoimmunity,” Frontiers in Immunology 9 (2018): 2306.
- 9J. C. de la Fuente-Mancera, I. Forado-Bentar, and M. Farrero, “Management of Long-Term Cardiovascular Risk Factors Post Organ Transplant,” Current Opinion in Organ Transplantation 27, no. 1 (2022): 29–35.
- 10S. Qin, L. Xu, M. Yi, S. Yu, K. Wu, and S. Luo, “Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4,” Molecular Cancer 18, no. 1 (2019): 155.
- 11C. Demerlé, L. Gorvel, and D. Olive, “BTLA–HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer,” Frontiers in Oncology 11 (2021): 682007.
- 12X. Xu, B. Hou, A. Fulzele, et al., “PD-1 and BTLA Regulate T Cell Signaling Differentially and Only Partially Through SHP1 and SHP2,” Journal of Cell Biology 219, no. 6 (2020): e201905085.
- 13X. Yu, Y. Zheng, R. Mao, Z. Su, and J. Zhang, “BTLA–HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection,” Frontiers in Immunology 10 (2019): 617.
- 14M. L. del Rio, J. Kaye, and J. I. Rodriguez-Barbosa, “Detection of Protein on BTLAlow Cells and In Vivo Antibody-Mediated Down-Modulation of BTLA on Lymphoid and Myeloid Cells of C57BL/6 and BALB/c BTLA Allelic Variants,” Immunobiology 215, no. 7 (2010): 570–578.
- 15A. De Sousa Linhares, J. Leitner, K. Grabmeier-Pfistershammer, and P. Steinberger, “Not All Immune Checkpoints Are Created Equal,” Frontiers in Immunology 9 (2018): 1909.
- 16I. Le Mercier, J. L. Lines, and R. J. Noelle, “Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators,” Frontiers in Immunology 6 (2015): 418.
- 17K. Wojciechowicz, M. Spodzieja, and A. Wardowska, “The BTLA–HVEM Complex—The Future of Cancer Immunotherapy,” European Journal of Medicinal Chemistry 268 (2024): 116231.
- 18J. I. Rodriguez-Barbosa, P. Schneider, A. Weigert, et al., “HVEM, a Cosignaling Molecular Switch, and Its Interactions With BTLA, CD160 and LIGHT,” Cellular & Molecular Immunology 16, no. 7 (2019): 679–682.
- 19M. L. del Rio, P. Schneider, C. Fernandez-Renedo, J. A. Perez-Simon, and J. I. Rodriguez-Barbosa, “LIGHT/HVEM/LTβR Interaction as a Target for the Modulation of the Allogeneic Immune Response in Transplantation,” American Journal of Transplantation 13, no. 3 (2013): 541–551.
- 20P. D'Arrigo, M. Tufano, A. Rea, et al., “Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules,” Current Medicinal Chemistry 27, no. 15 (2020): 2402–2448, https://doi.org/10.2174/0929867325666181106114421.
- 21M. A. Hurchla, J. R. Sedy, and K. M. Murphy, “Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival During Chronic Allostimulation,” Journal of Immunology 178, no. 10 (2007): 6073–6082.
- 22T. C. Cheung, M. W. Steinberg, L. M. Oborne, et al., “Unconventional Ligand Activation of Herpesvirus Entry Mediator Signals Cell Survival,” Proceedings of the National Academy of Sciences of the United States of America 106, no. 15 (2009): 6244–6249, https://doi.org/10.1073/pnas.0902115106.
- 23Z. Ning, K. Liu, and H. Xiong, “Roles of BTLA in Immunity and Immune Disorders,” Frontiers in Immunology 12 (2021): 654960.
- 24N. Otsuki, Y. Kamimura, M. Hashiguchi, and M. Azuma, “Expression and Function of the B and T Lymphocyte Attenuator (BTLA/CD272) on Human T Cells,” Biochemical and Biophysical Research Communications 344, no. 4 (2006): 1121–1127.
- 25C. Krieg, O. Boyman, Y. X. Fu, and J. Kaye, “B and T Lymphocyte Attenuator Regulates CD8+ T Cell-Intrinsic Homeostasis and Memory Cell Generation,” Nature Immunology 8, no. 2 (2007): 162–171.
- 26C. Deppong, J. M. Degnan, T. L. Murphy, K. M. Murphy, and J. M. Green, “B and T Lymphocyte Attenuator Regulates T Cell Survival in the Lung,” Journal of Immunology 181, no. 5 (2008): 2973–2979.
- 27X. Liu, M. Alexiou, N. Martin-Orozco, et al., “Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction,” Journal of Immunology 182, no. 8 (2009): 4516–4520.
- 28Y. Hu, Q. Hu, Y. Li, et al., “γδ T Cells: Origin and Fate, Subsets, Diseases and Immunotherapy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 434.
- 29H. J. Hwang, J. J. Lee, S. H. Kang, et al., “The BTLA and PD-1 Signaling Pathways Independently Regulate the Proliferation and Cytotoxicity of Human Peripheral Blood γδ T Cells,” Immunity, Inflammation and Disease 9, no. 1 (2021): 274–287.
- 30V. Bekiaris, J. R. Šedý, M. G. Macauley, A. Rhode-Kurnow, and C. F. Ware, “The Inhibitory Receptor BTLA Controls γδ T Cell Homeostasis and Inflammatory Responses,” Immunity 39, no. 6 (2013): 1082–1094.
- 31L. Karabon, A. Partyka, L. Ciszak, et al., “Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients,” Journal of Immunology Research 2020 (2020): 6545921.
- 32C. Sordo-Bahamonde, S. Lorenzo-Herrero, R. Granda-Díaz, et al., “Beyond the Anti-PD-1/PD-L1 Era: Promising Role of the BTLA–HVEM Axis as a Future Target for Cancer Immunotherapy,” Molecular Cancer 22, no. 1 (2023): 142.
- 33S. Kannan, R. K. Kurupati, S. A. Doyle, G. J. Freeman, K. E. Schmader, and H. C. Ertl, “BTLA Expression Declines on B Cells of the Aged and Is Associated With Low Responsiveness to the Trivalent Influenza Vaccine,” Oncotarget 6, no. 23 (2015): 19445–19455.
- 34N. Watanabe, M. Gavrieli, J. R. Sedy, et al., “BTLA Is a Lymphocyte Inhibitory Receptor With Similarities to CTLA-4 and PD-1,” Nature Immunology 4, no. 7 (2003): 670–679, https://doi.org/10.1038/ni944.
- 35A. C. Vendel, J. Calemine-Fenaux, A. Izrael-Tomasevic, V. Chauhan, D. Arnott, and D. L. Eaton, “B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK,” Journal of Immunology 182, no. 3 (2009): 1509–1517.
- 36M. A. Mintz, J. H. Felce, M. Y. Chou, et al., “The HVEM–BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis,” Immunity 51, no. 2 (2019): 310–323.
- 37M. L. Thibult, J. P. Rivals, E. Mamessier, et al., “CpG-ODN-Induced Sustained Expression of BTLA Mediating Selective Inhibition of Human B Cells,” Journal of Molecular Medicine 91, no. 2 (2013): 195–205.
- 38S. Vanamee É and D. L. Faustman, “The Benefits of Clustering in TNF Receptor Superfamily Signaling,” Frontiers in Immunology 14 (2023): 1225704.
- 39A. C. Vendel, L. Jaroszewski, M. D. Linnik, and A. Godzik, “B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis,” Clinical Pharmacology and Therapeutics 116, no. 1 (2024): 247–256.
- 40H. Xin, J. Zhu, H. Miao, et al., “Adenovirus-Mediated CCR7 and BTLA Overexpression Enhances Immune Tolerance and Migration in Immature Dendritic Cells,” BioMed Research International 2017 (2017): 3519745.
- 41A. Jones, J. Bourque, L. Kuehm, et al., “Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells,” Immunity 45, no. 5 (2016): 1066–1077.
- 42J. A. Zhang, Y. B. Lu, W. D. Wang, et al., “BTLA-Expressing Dendritic Cells in Patients With Tuberculosis Exhibit Reduced Production of IL-12/IFN-α and Increased Production of IL-4 and TGF-β, Favoring Th2 and Foxp3(+) Treg Polarization,” Frontiers in Immunology 11 (2020): 518.
- 43M. F. Chevalier, P. Bohner, C. Pieraerts, et al., “Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer,” European Urology 71, no. 6 (2017): 854–857.
- 44J. R. Sedy, M. Gavrieli, K. G. Potter, et al., “B and T Lymphocyte Attenuator Regulates T Cell Activation Through Interaction With Herpesvirus Entry Mediator,” Nature Immunology 6, no. 1 (2005): 90–98.
- 45T. L. Murphy and K. M. Murphy, “Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM,” Annual Review of Immunology 28 (2010): 389–411.
- 46C. Zhang, G. Zhang, N. Sun, et al., “Comprehensive Molecular Analyses of a TNF Family-Based Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Lung Adenocarcinoma,” eBioMedicine 59 (2020): 102959.
- 47L. K. Ward-Kavanagh, W. W. Lin, J. R. Sedy, and C. F. Ware, “The TNF Receptor Superfamily in Co-Stimulating and Co-Inhibitory Responses,” Immunity 44, no. 5 (2016): 1005–1019.
- 48C. Dostert, M. Grusdat, E. Letellier, and D. Brenner, “The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond,” Physiological Reviews 99, no. 1 (2019): 115–160.
- 49D. M. Compaan, L. C. Gonzalez, I. Tom, K. M. Loyet, D. Eaton, and S. G. Hymowitz, “Attenuating Lymphocyte Activity,” Journal of Biological Chemistry 280, no. 47 (2005): 39553–39561.
- 50R. Kojima, M. Kajikawa, M. Shiroishi, K. Kuroki, and K. Maenaka, “Molecular Basis for Herpesvirus Entry Mediator Recognition by the Human Immune Inhibitory Receptor CD160 and Its Relationship to the Cosignaling Molecules BTLA and LIGHT,” Journal of Molecular Biology 413, no. 4 (2011): 762–772.
- 51J. R. Sedy and P. Ramezani-Rad, “HVEM Network Signaling in Cancer,” Advances in Cancer Research 142 (2019): 145–186.
- 52M. Spodzieja, K. Kuncewicz, A. Sieradzan, et al., “Disulfide-Linked Peptides for Blocking BTLA–HVEM Binding,” International Journal of Molecular Sciences 21, no. 2 (2020): 636.
- 53K. Kuncewicz, C. Battin, A. Sieradzan, et al., “Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies,” International Journal of Molecular Sciences 21, no. 22 (2020): 8876.
- 54Y. Zhu, S. Yao, M. M. Augustine, et al., “Neuron-Specific SALM5 Limits Inflammation in the CNS via Its Interaction With HVEM,” Science Advances 2, no. 4 (2016): e1500637.
- 55L. Oumeslakht, A. I. Aziz, A. Bensussan, and S. Ben Mkaddem, “CD160 Receptor in CLL: Current State and Future Avenues,” Frontiers in Immunology 13 (2022): 1028013.
- 56C. Bossen, K. Ingold, A. Tardivel, et al., “Interactions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human,” Journal of Biological Chemistry 281, no. 20 (2006): 13964–13971.
- 57M. L. del Rio, C. Fernandez-Renedo, O. Chaloin, et al., “Immunotherapeutic Targeting of LIGHT/LTbetaR/HVEM Pathway Fully Recapitulates the Reduced Cytotoxic Phenotype of LIGHT-Deficient T Cells,” MAbs 8, no. 3 (2016): 478–490.
- 58C. W. Shuptrine, V. M. Perez, S. R. Selitsky, T. H. Schreiber, and G. Fromm, “Shining a LIGHT on Myeloid Cell Targeted Immunotherapy,” European Journal of Cancer 187 (2023): 147–160.
- 59K. Kuncewicz, C. Battin, K. Węgrzyn, et al., “Targeting the HVEM Protein Using a Fragment of Glycoprotein D to Inhibit Formation of the BTLA–HVEM Complex,” Bioorganic Chemistry 122 (2022): 105748.
- 60Y. Sakoda, J. J. Park, Y. Zhao, et al., “Dichotomous Regulation of GVHD Through Bidirectional Functions of the BTLA–HVEM Pathway,” Blood 117, no. 8 (2011): 2506–2514.
- 61J. Zhang, H. Zhang, Z. Wang, et al., “Author Correction: BTLA Suppress Acute Rejection via Regulating TCR Downstream Signals and Cytokines Production in Kidney Transplantation and Prolonged Allografts Survival,” Scientific Reports 12, no. 1 (2022): 21175, https://doi.org/10.1038/s41598-022-24559-x.
- 62H. Zhang, Z. Wang, J. Zhang, et al., “The Synergism of B and T Lymphocyte Attenuator (BTLA) and Cytotoxic T Lymphocyte Associated Antigen-4 (CTLA-4) Attenuated Acute T-Cell Mediated Rejection and Prolonged Renal Graft Survival,” Translational Andrology and Urology 9, no. 5 (2020): 1990–1999.
- 63H. Zhang, Z. Wang, J. Zhang, et al., “Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation,” Frontiers in Immunology 12 (2021): 618737.
- 64T. C. Cheung, I. R. Humphreys, K. G. Potter, et al., “Evolutionarily Divergent Herpesviruses Modulate T Cell Activation by Targeting the Herpesvirus Entry Mediator Cosignaling Pathway,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 37 (2005): 13218–13223.
- 65T. Dornieden, B. Wilde, J. Korth, et al., “Enhancement of Cytomegalovirus-Specific Cytokine Production After Modulation of the Costimulation in Kidney Transplant Patients,” Journal of Immunology Research 2019 (2019): 3926175.
- 66R. F. Duarte, M. Labopin, P. Bader, et al., “Indications for Haematopoietic Stem Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2019,” Bone Marrow Transplantation 54, no. 10 (2019): 1525–1552, https://doi.org/10.1038/s41409-019-0516-2.
- 67O. Penack, M. Marchetti, M. Aljurf, et al., “Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation,” Lancet Haematology 11, no. 2 (2024): e147–e159.
- 68E. H. Meyer, G. Laport, B. J. Xie, et al., “Transplantation of Donor Grafts With Defined Ratio of Conventional and Regulatory T Cells in HLA-Matched Recipients,” JCI Insight 4, no. 10 (2019): e127244, https://doi.org/10.1172/jci.insight.127244.
- 69T. L. Ramos, S. Bolivar-Wagers, S. Jin, et al., “Prevention of Acute GVHD Using an Orthogonal IL-2/IL-2Rβ System to Selectively Expand Regulatory T Cells In Vivo,” Blood 141, no. 11 (2023): 1337–1352, https://doi.org/10.1182/blood.2022018440.
- 70L. Zhao, S. Chen, P. Yang, H. Cao, and L. Li, “The Role of Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation: Prevention and Treatment of Graft-Versus-Host Disease,” Stem Cell Research & Therapy 10, no. 1 (2019): 182.
- 71A. Markov, L. Thangavelu, S. Aravindhan, et al., “Mesenchymal Stem/Stromal Cells as a Valuable Source for the Treatment of Immune-Mediated Disorders,” Stem Cell Research & Therapy 12, no. 1 (2021): 192.
- 72Y. Li, N. Wang, X. Zhang, et al., “Post-Transplantation Cyclophosphamide as GVHD Prophylaxis in Allogenic Hematopoietic Stem Cell Transplantation: Recent Advances and Modification,” Blood Reviews 62 (2023): 101078.
- 73E. Yazdandoust, A. Hajifathali, E. Roshandel, et al., “Gut Microbiota Intervention by Pre and Probiotics Can Induce Regulatory T Cells and Reduce the Risk of Severe Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation,” Transplant Immunology 78 (2023): 101836.
- 74M. L. del Rio, J. Kurtz, C. Perez-Martinez, A. Ghosh, J. A. Perez-Simon, and J. I. Rodriguez-Barbosa, “B- and T-Lymphocyte Attenuator Targeting Protects Against the Acute Phase of Graft Versus Host Reaction by Inhibiting Donor Anti-Host Cytotoxicity,” Transplantation 92, no. 10 (2011): 1085–1093.
- 75W. Hobo, W. J. Norde, N. Schaap, et al., “B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation,” Journal of Immunology 189, no. 1 (2012): 39–49.
- 76J. I. Rodriguez-Barbosa, C. Fernandez-Renedo, A. M. B. Moral, L. Bühler, and M. L. Del Rio, “T Follicular Helper Expansion and Humoral-Mediated Rejection Are Independent of the HVEM–BTLA Pathway,” Cellular & Molecular Immunology 14, no. 6 (2017): 497–510.
- 77M. L. del Rio, N. D. Jones, L. Buhler, et al., “Selective Blockade of Herpesvirus Entry Mediator-B and T Lymphocyte Attenuator Pathway Ameliorates Acute Graft-Versus-Host Reaction,” Journal of Immunology 188, no. 10 (2012): 4885–4896.
- 78A. M. Shapiro, M. Pokrywczynska, and C. Ricordi, “Clinical Pancreatic Islet Transplantation,” Nature Reviews. Endocrinology 13, no. 5 (2017): 268–277.
- 79K. Khan and C. S. Desai, “Islet Transplantation in Children,” Current Gastroenterology Reports 21, no. 6 (2019): 26.
- 80N. Sato and S. Marubashi, “Induction of Immune Tolerance in Islet Transplantation Using Apoptotic Donor Leukocytes,” Journal of Clinical Medicine 10, no. 22 (2021): 5306, https://doi.org/10.3390/jcm10225306.
- 81Q. Ding, M. Yeung, G. Camirand, et al., “Regulatory B Cells Are Identified by Expression of TIM-1 and Can Be Induced Through TIM-1 Ligation to Promote Tolerance in Mice,” Journal of Clinical Investigation 121, no. 9 (2011): 3645–3656.
- 82A. Scuteri, E. Donzelli, V. Rodriguez-Menendez, et al., “A Double Mechanism for the Mesenchymal Stem Cells' Positive Effect on Pancreatic Islets,” PLoS One 9, no. 1 (2014): e84309.
- 83A. J. Vegas, O. Veiseh, M. Gurtler, et al., “Long-Term Glycemic Control Using Polymer-Encapsulated Human Stem Cell-Derived Beta Cells in Immune-Competent Mice,” Nature Medicine 22, no. 3 (2016): 306–311.
- 84H. Rahavi, S. M. Hashemi, M. Soleimani, J. Mohammadi, and N. Tajik, “Adipose Tissue-Derived Mesenchymal Stem Cells Exert In Vitro Immunomodulatory and Beta Cell Protective Functions in Streptozotocin-Induced Diabetic Mice Model,” Journal Diabetes Research 2015 (2015): 878535.
- 85X. Wang, N. K. Brown, B. Wang, et al., “Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells,” Advanced Science 8, no. 17 (2021): e2003708.
- 86A. Dangi, S. Yu, F. T. Lee, et al., “Donor Apoptotic Cell-Based Therapy for Effective Inhibition of Donor-Specific Memory T and B Cells to Promote Long-Term Allograft Survival in Allosensitized Recipients,” American Journal of Transplantation 20, no. 10 (2020): 2728–2739.
- 87H. Masaoka, Y. Yamamoto, M. Uchiyama, et al., “Graft Protective and Intercellular Immunomodulatory Effects by Adoptive Transfer of an Agonistic Anti-BTLA mAb (3C10) Induced CD4(+)CD25(+) Regulatory T Cells in Murine Cardiac Allograft Transplant Model,” Transplantation Proceedings 56 (2024): 692–700.
- 88W. Truong, J. C. Plester, W. W. Hancock, et al., “Negative and Positive Co-Signaling With Anti-BTLA (PJ196) and CTLA4Ig Prolongs Islet Allograft Survival,” Transplantation 84, no. 10 (2007): 1368–1372.
- 89E. B. Thorp, C. Stehlik, and M. J. Ansari, “T-Cell Exhaustion in Allograft Rejection and Tolerance,” Current Opinion in Organ Transplantation 20, no. 1 (2015): 37–42.
- 90G. M. Marrón-Liñares, L. Núñez, and M. Hermida-Prieto, “LIGHT/BTLA Polymorphisms and Antibody-Mediated-Rejection After Heart Transplantation,” Oncotarget 9, no. 88 (2018): 35799–35800.
- 91M. Uchiyama, X. Jin, H. Matsuda, et al., “An Agonistic Anti-BTLA mAb (3C10) Induced Generation of IL-10-Dependent Regulatory CD4+ T Cells and Prolongation of Murine Cardiac Allograft,” Transplantation 97, no. 3 (2014): 301–309.
- 92J. C. Albring, M. M. Sandau, A. S. Rapaport, et al., “Targeting of B and T Lymphocyte Associated (BTLA) Prevents Graft-Versus-Host Disease Without Global Immunosuppression,” Journal of Experimental Medicine 207, no. 12 (2010): 2551–2559.
- 93J. Zhang, H. Zhang, Z. Wang, et al., “BTLA Suppress Acute Rejection via Regulating TCR Downstream Signals and Cytokines Production in Kidney Transplantation and Prolonged Allografts Survival,” Scientific Reports 9, no. 1 (2019): 12154.
- 94Z. Wang, H. Yang, X. Liu, et al., “Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients With Biopsy-Proven Acute Rejection,” Medical Science Monitor 24 (2018): 387–396.
- 95R. Tao, L. Wang, R. Han, et al., “Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially Versus Fully MHC-Mismatched Cardiac Allografts,” Journal of Immunology 175, no. 9 (2005): 5774–5782.
- 96W. Truong, J. C. Plester, W. W. Hancock, et al., “Combined Coinhibitory and Costimulatory Modulation With Anti-BTLA and CTLA4Ig Facilitates Tolerance in Murine Islet Allografts,” American Journal of Transplantation 7, no. 12 (2007): 2663–2674, https://doi.org/10.1111/j.1600-6143.2007.01996.x.
- 97R. Labrosse, I. Boufaied, B. Bourdin, et al., “Aberrant T-Cell Exhaustion in Severe Combined Immunodeficiency Survivors With Poor T-Cell Reconstitution After Transplantation,” Journal of Allergy and Clinical Immunology 151, no. 1 (2023): 260–271.
- 98Q. Guan, S. G. Gilpin, J. Doerksen, et al., “The Interactions of T Cells With Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts,” Cells 13, no. 18 (2024): 1545.
- 99W. Truong, W. W. Hancock, J. C. Plester, et al., “BTLA Targeting Modulates Lymphocyte Phenotype, Function, and Numbers and Attenuates Disease in Nonobese Diabetic Mice,” Journal of Leukocyte Biology 86, no. 1 (2009): 41–51, https://doi.org/10.1189/jlb.1107753.
- 100M. W. Steinberg, O. Turovskaya, R. B. Shaikh, et al., “A Crucial Role for HVEM and BTLA in Preventing Intestinal Inflammation,” Journal of Experimental Medicine 205, no. 6 (2008): 1463–1476, https://doi.org/10.1084/jem.20071160.
- 101A. Crawford and E. J. Wherry, “Editorial: Therapeutic Potential of Targeting BTLA,” Journal of Leukocyte Biology 86, no. 1 (2009): 5–8.
- 102S. Iida, S. Miyairi, C. A. Su, et al., “Peritransplant VLA-4 Blockade Inhibits Endogenous Memory CD8 T Cell Infiltration Into High-Risk Cardiac Allografts and CTLA-4Ig Resistant Rejection,” American Journal of Transplantation 19, no. 4 (2019): 998–1010.
- 103J. Chen, Q. Wang, D. Yin, V. Vu, R. Sciammas, and A. S. Chong, “Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients,” Journal of Immunology 195, no. 9 (2015): 4069–4073.
